Biotech Acquisition Co (BIOT) SEC Filing 425 Merger Prospectus

Biotech Acquisition Co

CIK: 1825413 Ticker: BIOT

View differences made from one to another to evaluate Biotech Acquisition Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 425 Merger Prospectus to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biotech Acquisition Co.


Assess how Biotech Acquisition Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Biotech Acquisition Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: BIOT
CIK: 1825413
Form Type: 425 Merger Prospectus
Accession Number: 0001213900-22-027176
Submitted to the SEC: Mon May 16 2022 4:33:47 PM EST
Accepted by the SEC: Mon May 16 2022
Industry: Blank Checks

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: